• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

    8/20/24 7:00:06 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CING alert in real time by email
    SC 13D/A 1 formsc13da.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 16)*

     

    Cingulate Inc.
    (Name of Issuer)
     
    COMMON STOCK, PAR VALUE $0.0001 PER SHARE
    (Title of Class of Securities)
     
    17248W303
    (CUSIP Number)
     

    Shane J. Schaffer

    Chief Executive Officer

    1901 W. 47th Place

    Kansas City, KS 66205

    Telephone Number (913) 942-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     
    August 16, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     

     

     
     

     

    CUSIP No. 17248W303  
    1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only):  
      Peter J. Werth  
    2. Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐
    3. SEC Use Only  
    4. Source of Funds (See Instructions): PF  
    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):  
      ☐  
    6. Citizenship or Place of Organization: United States  

      Number of 7. Sole Voting Power: 213*
      Shares Beneficially 8. Shared Voting Power: 98,029*
      Owned by    
      Each Reporting 9. Sole Dispositive Power: 213*
      Person With 10. Shared Dispositive Power: 98,029*

    11. Aggregate Amount Beneficially Owned by Each Reporting Person:
      98,242*
    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):
      ☐
    13. Percent of Class Represented by Amount in Row (11): 5.68%*
    14. Type of Reporting Person (See Instructions): IN

     

    *As of the date hereof, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Peter J. Werth (“Mr. Werth”) may be deemed to beneficially own an aggregate of 98,242 shares of common stock, par value $0.0001 per share (the “Common Stock”), of Cingulate Inc. (the “Issuer”) consisting of (i) 92 shares of Common Stock and stock options to purchase 121 shares of Common Stock held directly by Mr. Werth and (ii) 97,994 shares of Common Stock and warrants to purchase up to 35 shares of Common Stock held directly by Werth Family Investment Associates LLC (“Werth Associates”) where Mr. Werth serves as Manager. Excludes 1,583 shares of Common Stock underlying unvested stock options held directly by Mr. Werth.

     

    The foregoing reported beneficial ownership percentage is based upon 1,729,419 shares of Common Stock issued and outstanding as of August 16, 2024. The number of shares of Common Stock issued and outstanding reflects the 1-for-20 and 1-for-12 reverse stock splits of the Issuer’s issued and outstanding shares of Common Stock, which became effective on November 30, 2023 and August 9, 2024, respectively.

     

     
     

     

    CUSIP No. 17248W303  
    1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only):  
      Werth Family Investment Associates LLC  
    2. Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐
    3. SEC Use Only  
    4. Source of Funds (See Instructions): WC  
    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):  
      ☐  
    6. Citizenship or Place of Organization: Connecticut  

      Number of 7. Sole Voting Power: 0
      Shares Beneficially 8. Shared Voting Power: 98,029**
      Owned by    
      Each Reporting 9. Sole Dispositive Power: 0
      Person With 10. Shared Dispositive Power: 98,029**

    11. Aggregate Amount Beneficially Owned by Each Reporting Person:
      98,029**
    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):
      ☐
    13. Percent of Class Represented by Amount in Row (11): 5.67%**
    14. Type of Reporting Person (See Instructions): OO

     

    ** As of the date hereof, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Werth Family Investment Associates LLC (“Werth Associates”) may be deemed to beneficially own 98,029 shares of common stock, par value $0.0001 per share (the “Common Stock”), of Cingulate Inc. (the “Issuer”), consisting of 97,994 shares of Common Stock and warrants to purchase up to 35 shares of Common Stock.

     

    The foregoing reported beneficial ownership percentage is based upon 1,729,419 shares of Common Stock issued and outstanding as of August 16, 2024. The number of shares of Common Stock issued and outstanding reflects the 1-for-20 and 1-for-12 reverse stock splits of the Issuer’s issued and outstanding shares of Common Stock, which became effective on November 30, 2023 and August 9, 2024, respectively.

     

     
     

     

    Explanatory Note

     

    This Amendment No. 16 (this “Amendment”) amends and supplements the Schedule 13D filed on behalf of the Reporting Persons with the Securities and Exchange Commission on December 20, 2021, as amended on December 23, 2022, July 25, 2023, August 14, 2023, September 18, 2023, November 8, 2023, January 4, 2024, January 29, 2024, February 9, 2024, February 28, 2024, April 12, 2024, May 28, 2024, June 7, 2024, June 27, 2024, July 2, 2024 and July 16, 2024 (the “Schedule 13D”). Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

     

    The number of shares of Common Stock issued and outstanding reflects the 1-for-20 and 1-for-12 reverse stock splits of the Issuer’s issued and outstanding shares of Common Stock, which became effective on November 30, 2023 and August 9, 2024, respectively.

     

     
     

     

    Item 5. Interest in Securities of the Issuer.

     

    The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover page of this Schedule 13D and the information set forth in or incorporated by reference in Item 2, Item 3 and Item 6 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 5.

     

    The aggregate percentage of Common Stock reported owned by the Reporting Persons is based upon 1,729,419 shares of Common Stock outstanding, which is the total number of shares of Common Stock outstanding as of August 16, 2024. The number of shares of Common Stock issued and outstanding reflects the 1-for-20 and 1-for-12 reverse stock splits of the Issuer’s issued and outstanding shares of Common Stock, which became effective on November 30, 2023 and August 9, 2024, respectively.

     

    As of the date hereof, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Mr. Werth may be deemed to beneficially own 98,242 shares of Common Stock of the Issuer, consisting of (i) 92 shares of Common Stock and stock options to purchase 121 shares of Common Stock held directly by Mr. Werth and (ii) 97,994 shares of Common Stock and warrants to purchase up to 35 shares of Common Stock held directly by Werth Associates.

     

    Except as described herein, during the past sixty (60) days on or prior to the date hereof, there were no other purchases or sales of shares of Common Stock, or securities convertible into or exchangeable for shares of Common Stock, by the Reporting Persons or any person or entity for which the Reporting Persons possess voting or dispositive control over the securities thereof.

     

     
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      August 20, 2024
         
      By: /s/ Peter J. Werth*
        Peter J. Werth
         
      WERTH FAMILY INVESTMENT ASSOCIATES LLC
         
      By: Peter J. Werth, its Manager
         
      By: /s/ Peter J. Werth
      Name: Peter J. Werth
      Title: Manager

     

    * This reporting person disclaims beneficial ownership of these reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose.

     

    Attention: Intentional misstatements or omissions of fact constitute
    Federal criminal violations (see 18 U.S.C. 1001).

     

     

    Get the next $CING alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CING

    DatePrice TargetRatingAnalyst
    1/10/2025$12.00Buy
    ROTH MKM
    12/22/2023Buy → Hold
    Laidlaw
    1/20/2022$8.50Buy
    Laidlaw & Co.
    1/11/2022$9.00Buy
    Aegis Capital
    More analyst ratings

    $CING
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Cingulate with a new price target

    ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

    1/10/25 7:39:52 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate downgraded by Laidlaw

    Laidlaw downgraded Cingulate from Buy to Hold

    12/22/23 7:22:08 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Laidlaw & Co. initiated coverage on Cingulate with a new price target

    Laidlaw & Co. initiated coverage of Cingulate with a rating of Buy and set a new price target of $8.50

    1/20/22 9:15:46 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CLO and CCO Patel Nilay Dahyabhai

    4 - Cingulate Inc. (0001862150) (Issuer)

    7/10/25 6:02:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Patel Nilay Dahyabhai

    3 - Cingulate Inc. (0001862150) (Issuer)

    7/10/25 6:00:15 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP and CSO Silva Raul R.

    4 - Cingulate Inc. (0001862150) (Issuer)

    7/9/25 6:00:13 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

    Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2025, and provided recent highlights. Recent Highlights: On July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation

    8/19/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Provides Management Team Update

    Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:CING) The Board of Directors of Cingulate Inc. ("Cingulate") announced that it has placed Chairman and Chief Executive Officer, Shane J. Schaffer, PharmD, on administrative leave in connection with ongoing legal matters unrelated to the company and its operations. In addition, Jennifer Callahan, Cingulate's Chief Financial Officer, has been appointed interim CEO to ensure business continuity and operational stability. Ms. Callahan will retain her responsibilities as Chief Financial Officer. Healthcare in

    8/15/25 9:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

    KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CTx-1301(dexmethylphenidate HCl), the company's lead asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). CTx-1301 is a novel, extended-release tablet formulation of dexmethylphenidate designed to deliver fast onset, entire active-day efficacy, and a smooth pharmacokinet

    8/6/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Callahan Jennifer L. bought $1,490 worth of shares (55 units at $27.10), increasing direct ownership by 2% to 2,333 units (SEC Form 4)

    4 - Cingulate Inc. (0001862150) (Issuer)

    3/22/24 6:00:15 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Callahan Jennifer L. bought $3,348 worth of shares (5,000 units at $0.67), increasing direct ownership by 12% to 45,508 units

    4 - Cingulate Inc. (0001862150) (Issuer)

    9/18/23 6:00:26 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    SEC Filings

    View All

    SEC Form 10-Q filed by Cingulate Inc.

    10-Q - Cingulate Inc. (0001862150) (Filer)

    8/19/25 8:56:21 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cingulate Inc. (0001862150) (Filer)

    8/19/25 8:50:51 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Cingulate Inc.

    DEF 14A - Cingulate Inc. (0001862150) (Filer)

    8/15/25 4:30:24 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

    SC 13G/A - Cingulate Inc. (0001862150) (Subject)

    11/14/24 7:21:05 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

    SC 13D/A - Cingulate Inc. (0001862150) (Subject)

    8/30/24 6:00:22 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

    SC 13D/A - Cingulate Inc. (0001862150) (Subject)

    8/20/24 7:00:06 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CING
    Leadership Updates

    Live Leadership Updates

    View All

    Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

    KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, has named Nilay Patel, JD, as Chief Legal Officer. Patel's appointment comes as Cingulate plans to submit a new drug application to the FDA in coming weeks for its lead asset CTx-1301 (dexmethylphenidate HCl) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Mr. Patel brings more than two decades of legal and compliance leadership in the pharmaceutical industry, having advised companies across

    7/9/25 8:00:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer

    Industry Leader with 30+ Years of Experience Will Drive Strategic Growth and Partnerships SCOTTSDALE, Ariz., May 27, 2025 /PRNewswire/ -- Life365, a leading data engagement and virtual care company, today announced the appointment of healthcare executive and investor Jay Roberts as chief development officer. Roberts, who previously served as an executive advisor to Life365, brings more than 30 years of strategic healthcare leadership experience to this pivotal role. Life365's platform enables the next generation of AI-driven healthcare for enterprise healthcare organizations,

    5/27/25 10:05:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

    KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin. The appointment of the new directors follows the completion of the Company's recent follow-on offering of $7.5 million in February 2024, sales under the Company's at-the-market offering (ATM) facility in January 2024 of $3.2 million, as well as the conversion of $3.3 million of outstanding debt i

    2/13/24 6:45:00 AM ET
    $BACK
    $CING
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $CING
    Financials

    Live finance-specific insights

    View All

    Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

    Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026 KANSAS CITY, Kan., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2025, and provided recent highlights. Recent Highlights: On July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation

    8/19/25 8:45:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

    Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended March 31, 2025, and provided a clinical and business update. Highlights include the completion of the Pre-NDA meeting for CTx-1301 and grant received to accelerate

    5/8/25 4:30:00 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

    KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update. "The capital raised this quarter has allowed us to focus on advancing the remaining activities required for NDA submission of our lead ADHD asset, CTx-1301, targeted for mid 2025," said Cingulate Chairman and CEO Shane J. Schaffer. "The granting of European patents for CTx-1301 in up to

    11/7/24 7:30:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care